AbbVie's Humira approved for treating Crohn's in children

(AP) — AbbVie Inc. said U.S. regulators approved its drug Humira as a treatment for Crohn's disease in children.

Humira is the biggest-selling brand-name drug in the world, according to IMS Health. It is approved to treat conditions including Crohn's disease, rheumatoid arthritis, ulcerative colitis and plaque psoriasis.

The Food and Drug Administration cleared Humira as a treatment for moderate to severe Crohn's disease in children ages 6 and older when those children haven't been helped by other treatments, North Chicago-based AbbVie said today.

Humira can be administered at home, unlike similar drugs used to treat the condition, the company said.

Humira revenue jumped 26 percent to $3.29 billion in the second quarter.